New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
07:55 EDTNVDQNovadaq price target raised to $26 from $23 at Canaccord
Canaccord raised its price target on Novadaq calling it the most compelling growth story in med-tech because it possesses one of the largest TAM opportunities in their group. The firm expects the company to re-acquire US marketing rights for SPY Elite in 2015 and then go direct thereafter resulting in higher average selling prices. Shares are Buy rated.
News For NVDQ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for NVDQ

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use